Prognostic impact of (18)FDG-PET-CT findings in clinical stage III and IIB breast cancer.
about
Application of positron emission tomography (PET/CT) in diagnosis of breast cancer. Part I. Diagnosis of breast cancer prior to treatmentComparison of Whole-Body (18)F FDG PET/MR Imaging and Whole-Body (18)F FDG PET/CT in Terms of Lesion Detection and Radiation Dose in Patients with Breast Cancer.Do clinical, histological or immunohistochemical primary tumour characteristics translate into different (18)F-FDG PET/CT volumetric and heterogeneity features in stage II/III breast cancer?Optimal Modality for Detecting Distant Metastasis in Primary Nasopharyngeal Carcinoma during Initial Staging: A Systemic Review and Meta-analysis of 1774 PatientsIncrease in Distant Stage Breast Cancer Incidence Rates in US Women Aged 25-49 Years, 2000-2011: The Stage Migration HypothesisUtility of (18)F FDG-PET/CT for predicting prognosis of luminal-type breast cancer.Retrospective analysis of 18F-FDG PET/CT for staging asymptomatic breast cancer patients younger than 40 years.False Positive 18F-FDG Uptake in Mediastinal Lymph Nodes Detected with Positron Emission Tomography in Breast Cancer: A Case Report.Comparison of 18F-FDG PET/CT for Systemic Staging of Newly Diagnosed Invasive Lobular Carcinoma Versus Invasive Ductal Carcinoma.Predictive Ability of 18F-fluorodeoxyglucose Positron Emission Tomography/computed Tomography for Pathological Complete Response and Prognosis after Neoadjuvant Chemotherapy in Triple-negative Breast Cancer Patients.Gastrin-releasing Peptide Receptor Imaging in Breast Cancer Using the Receptor Antagonist (68)Ga-RM2 And PET.Detection of Internal Mammary Adenopathy in Patients With Breast Cancer by PET/CT and MRI.HER2-overexpressing breast cancer: FDG uptake after two cycles of chemotherapy predicts the outcome of neoadjuvant treatmentAssociation between partial-volume corrected SUVmax and Oncotype DX recurrence score in early-stage, ER-positive/HER2-negative invasive breast cancer.18F-FDG uptake in breast cancer correlates with immunohistochemically defined subtypes.(18)F-FDG-PET/CT for systemic staging of newly diagnosed triple-negative breast cancer18F-FDG-PET/CT for systemic staging of patients with newly diagnosed ER-positive and HER2-positive breast cancer.Basal ¹⁸F-fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography as a prognostic biomarker in patients with locally advanced breast cancer.Prediction of breast cancer recurrence using lymph node metabolic and volumetric parameters from 18F-FDG PET/CT in operable triple-negative breast cancer.Correlation between tumour characteristics, SUV measurements, metabolic tumour volume, TLG and textural features assessed with 18F-FDG PET in a large cohort of oestrogen receptor-positive breast cancer patients.Prognostic impact of 18F-FDG PET/CT staging and of pathological response to neoadjuvant chemotherapy in triple-negative breast cancer.18F-FDG PET/CT in breast cancer: Evidence-based recommendations in initial staging.Role of bone scan in addition to CT in patients with breast cancer selected for systemic staging.Is (18)FDG uptake useful to decide on chemotherapy in ER+/HER2- breast cancer?FDG-PET/CT for systemic staging of patients with newly diagnosed breast cancer.Tumour and lymph node uptakes on dual-phased 2-deoxy-2-[18F]fluoro-D-glucose positron emission tomography/computed tomography correlate with prognostic parameters in breast cancer.¹⁸F-FDG PET/CT provides powerful prognostic stratification in the primary staging of large breast cancer when compared with conventional explorations.Breast cancer detection using high-resolution breast PET compared to whole-body PET or PET/CT.Estrogen receptor-positive/human epidermal growth factor receptor 2-negative breast tumors: early prediction of chemosensitivity with (18)F-fluorodeoxyglucose positron emission tomography/computed tomography during neoadjuvant chemotherapy.The value of 18F-FDG PET/CT imaging in breast cancer staging.Concerning pretreatment ¹⁸F-FDG PET/CT imaging in patients with large or locally advanced breast cancer.Role of 18F-Fluorodeoxyglucose Positron-Emission Tomography/Computed Tomography Scan in Primary Staging of Breast Cancer Compared to Conventional Staging.
P2860
Q26751999-E6A030EF-3E16-443A-969B-E73BB9378EF6Q31064473-B7E2439D-94B1-4E5F-BECF-B9A6CD8CFA2EQ33576007-F525F54A-B3FA-4BCC-BDA8-EE6E10531A4EQ33776738-6B343F00-976D-4912-8A09-B3DA6BAAF2B8Q35013062-DEDE30BD-0157-4DF6-9793-0DC4FF0211FEQ35131272-B48A5EEC-6DA4-4D64-9879-47B1E7AD438BQ35552138-0C7F8B6F-C1C3-4422-BF9A-8346BC780C7DQ36702891-DBAA32FE-9416-4F2C-9501-6783C5816DB5Q36908141-27F3DC10-0D4A-4AA7-AB8B-82A841E53466Q37077266-FEC7729C-6202-40A1-9BA4-1642ABB29CC7Q37112967-AC21E051-2E9C-467A-9DD2-E4DABCE3DD27Q37146074-D2627790-B7BB-47EF-ADCB-D685C6119382Q37185872-6651397E-7FCF-4BE6-B3E2-81CBE3822A00Q38414263-F234C9C2-BF25-497E-ADA1-0F770993C067Q38446353-03765E6F-7BD7-42D9-A537-E6AFA55E5DCFQ38821174-0707F2C5-BFAD-4ED9-A322-49D9C4EE5E6DQ39272681-EF0CF421-BA03-4D87-9795-51200C44167BQ42479479-1FBD2F93-9548-4DBE-AD4E-3C4E31B01334Q47856252-B3630617-A8BB-4A29-B464-73BE6EA4CA3FQ48047542-259EE0C1-C131-4C9D-8B13-2CDF2F401074Q48444536-3138FC2F-0B57-48E6-A0E1-A291C5F5FE9BQ50100711-F7F5DA35-F720-4D9B-B16A-FFC557D36AD0Q50867456-BD0CE85D-ABE2-478B-954D-8C3C2F37FF52Q51727954-5A1961CD-4FDB-43A0-9FB8-C73617626CEFQ52941027-F52703D1-A44C-4B02-963E-D786D386C7CDQ53043935-6863ECF5-11A3-4DC9-9484-1074BF270DA1Q53089607-EB65E2E8-01FB-4E7C-AFAE-93808F7F7A55Q53093553-3815BC47-70CF-4DD0-A993-BB10CA9690BFQ53116763-CC58DE9E-5207-4660-A1CB-445EB2DF5D7EQ53252041-ED84731C-73B3-4869-A0C9-CA4A6EE6BB15Q53396296-15115328-C387-447D-905B-8F3AB6B2853EQ55379188-9D1C6C72-CD0E-42C2-85D5-CFEC6A5CFF02
P2860
Prognostic impact of (18)FDG-PET-CT findings in clinical stage III and IIB breast cancer.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年学术文章
@wuu
2012年学术文章
@zh-cn
2012年学术文章
@zh-hans
2012年学术文章
@zh-my
2012年学术文章
@zh-sg
2012年學術文章
@yue
2012年學術文章
@zh
2012年學術文章
@zh-hant
name
Prognostic impact of (18)FDG-PET-CT findings in clinical stage III and IIB breast cancer.
@ast
Prognostic impact of (18)FDG-PET-CT findings in clinical stage III and IIB breast cancer.
@en
type
label
Prognostic impact of (18)FDG-PET-CT findings in clinical stage III and IIB breast cancer.
@ast
Prognostic impact of (18)FDG-PET-CT findings in clinical stage III and IIB breast cancer.
@en
prefLabel
Prognostic impact of (18)FDG-PET-CT findings in clinical stage III and IIB breast cancer.
@ast
Prognostic impact of (18)FDG-PET-CT findings in clinical stage III and IIB breast cancer.
@en
P2093
P2860
P50
P356
P1476
Prognostic impact of (18)FDG-PET-CT findings in clinical stage III and IIB breast cancer.
@en
P2093
Anne de Roquancourt
Cédric de Bazelaire
David Groheux
Elif Hindié
Laetitia Vercellino
Marc Espié
Marie-Elisabeth Toubert
Pascal Merlet
Sylvie Giacchetti
P2860
P304
P356
10.1093/JNCI/DJS451
P407
P577
2012-12-12T00:00:00Z